Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 06 May 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Adalimumab induces deep remission in patients with Crohn's disease 

The latest issue of the Clinical Gastroenterology & Hepatology assesses the relationships between deep remission and other outcomes among patients who received adalimumab.

News image

Patients with moderate to severe ileocolonic Crohn's disease (CD) who received adalimumab induction and maintenance therapy had greater rates of mucosal healing than patients who received placebo after adalimumab induction therapy in a 52-week trial (EXTend the Safety and Efficacy of Adalimumab Through ENDoscopic Healing).

Dr Jean–Frédéric Colombel and colleagues from New York, USA investigated whether this treatment also induced deep remission—a composite clinical and endoscopic end point.

Rates of deep remission, defined as the absence of mucosal ulceration and Crohn's disease Activity Index scores less than 150, were compared between patients given continuous adalimumab and those given only induction therapy followed by placebo.

The team assessed the relationships between deep remission and other outcomes among patients who received adalimumab.

Rates of deep remission were greatest among patients who received adalimumab
Clinical Gastroenterology & Hepatology

The outcomes of patients with deep remission were compared with those of patients with only the absence of mucosal ulceration or only clinical remission.

Rates of deep remission were 16% in patients given adalimumab vs 10% in those given placebo at week 12, and 19% vs 0% at week 52.

The research team found that rates of deep remission were greatest among patients who received adalimumab and had Crohn's disease for 2 years or less.

At week 52, patients who achieved deep remission at week 12 required significantly fewer adalimumab treatment adjustments, hospitalizations, and Crohn's disease-related surgeries.

The patients also had significantly less activity impairment, and had better quality of life and physical function compared with patients not achieving deep remission.

Deep remission generally was associated with better outcomes than only an absence of mucosal ulceration, outcomes of patients with deep remission vs only clinical remission were similar.

The team noted that deep remission was associated with estimated total cost savings of $10,360 compared with lack of deep remission.

Dr Colombel's team concludes, "In an exploratory study of patients with moderate to severe ileocolonic Crohn's disease who received adalimumab induction and maintenance therapy, patients achieving deep remission appeared to have better 1-year outcomes than those not achieving deep remission."

"These findings should be validated in large, prospective trials."

Clin Gastroenterol Hepatol 2014: 12(3): 414-422.e5
25 February 2014

Go to top of page Email this page Email this page to a colleague

 06 May 2016 
Managing acute lower GI bleeding
 06 May 2016 
Recurrent pancreatitis after acute pancreatitis
 06 May 2016 
Risk factors in peptic ulcer bleeding
 05 May 2016 
Genetics in early-early-onset IBD
 05 May 2016 
Reductions in quality of screening colonoscopies
 05 May 2016 
Chemoradiotherapy vs chemotherapy for pancreatic cancer
 04 May 2016 
Bismuth and H. pylori eradication
 04 May 2016 
Chromoendoscopy vs colonoscopy for dysplasia in colitis
 04 May 2016 
Anti-TNF therapy for IBD
 03 May 2016 
Surgery vs medical therapy for GERD
 03 May 2016 
Vedolizumab for IBD
 03 May 2016 
PPIs and gut microbiota
 02 May 2016 
Resection of colorectal polyps
 02 May 2016 
Genetic variant that increase NAFLD risk
 02 May 2016 
Mycophenolate mofetil as first-line treatment of autoimmune hepatitis
 29 April 2016 
Crohn's disease associated genes
 29 April 2016 
Simvastatins and survival in cirrhosis
 29 April 2016 
HCV infection in Baby Boomers with Medicare
 28 April 2016 
Racial disparities in survival from colon cancer
 28 April 2016 
Diarrheal diseases in children
 28 April 2016 
Birth outcomes in women with IBD receiving assisted reproduction
 27 April 2016 
Dust mite and human GI tract
 27 April 2016 
Ultra-short celiac disease
 27 April 2016 
Celiac disease in adults
 26 April 2016 
Polyp detection during colonoscopy
 26 April 2016 
Guidelines for nutrition therapy in hospitalized patients
 26 April 2016 
IBS and microscopic colitis
 25 April 2016 
Estrogen deficiency and fibrosis risk in women with NAFLD
 25 April 2016 
Abrupt interruption of beta-blockers in cirrhosis 
 25 April 2016 
Acceptance of Liver transplant center organ offers
 22 April 2016 
Novel method to regenerate the esophagus
 22 April 2016 
Relapse after antiviral treatment in Hep B
 22 April 2016 
Microscopic colitis with NSAIDs and PPIs
 11 April 2016 
Infliximab vs adalimumab in ulcerative colitis
 11 April 2016 
H. pylori in treatment-naïve children
 11 April 2016 
Admissions times and outcomes for ERCP cholangitis
 08 April 2016 
Endoscopic treatment of Crohn's strictures
 08 April 2016 
Nutrition therapy in the hospitalized patient
 08 April 2016 
H.pylori effects on pediatric gastric mucosa
 07 April 2016 
CVD changes after TIPSS
 07 April 2016 
Transanal mesorectal resection for rectal cancer
 07 April 2016 
HBV during immunosuppressive therapies
 06 April 2016 
Adherence to colorectal cancer screening strategies
 06 April 2016 
Duodenal bulb biopsies in childhood celiac disease diagnosis
 06 April 2016 
Lymph node metastasis in early gastric cancer
 05 April 2016 
Colorectal cancer risk with serrated polyps
 05 April 2016 
IBS in the US military
 05 April 2016 
Changes in blood flow in cirrhosis
 04 April 2016 
Noninvasive diagnosis of celiac disease
 04 April 2016 
Metallic vs plastic stents for benign biliary strictures
 04 April 2016 
Adherence to quality indicators improves clinical outcomes in ascites
 01 April 2016 
Intensive enteral nutrition and severe alcoholic hepatitis
 01 April 2016 
Prognosis after colorectal cancer resection with peritoneal metastasis
 01 April 2016 
Colorectal cancer risk with non-malignant colonoscopy findings
 31 March 2016 
Management of Barrett’s esophagus
 31 March 2016 
Anesthesia services during colonoscopy
 31 March 2016 
Alcohol and glucose tolerance in NAFLD
 30 March 2016 
Electronic learning system for colon capsule endoscopy
 30 March 2016 
Gastric cancer screening
 30 March 2016 
Depression and symptoms in IBS

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us